Table 6

Effect of PPAR-γ agonists on biochemical markers of bone turnover in rats with adjuvant arthritis

Group

Change in plasma osteocalcina (ng/ml)

Change in urinary deoxypyridinolineb (nmol/mmol creatinine)


Normal controls

-39 ± 11

-3 ± 6

AIA controls

-50 ± 9

24 ± 7*

AIA + ROSI 10

-37 ± 12

9 ± 4

AIA + PIO 30

-32 ± 16

12 ± 5


PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day. Data are expressed as means ± SEM (n = 5 for deoxypyridinoline; n = 6 for osteocalcin).

*, P < 0.05 compared with normal controls (ANOVA and Fisher's PLSD test). aDay 21 minus day -1; bday 21 minus day 0.

Koufany et al. Arthritis Research & Therapy 2008 10:R6   doi:10.1186/ar2354

Open Data